Beck Bode LLC Acquires Shares of 10,525 DexCom, Inc. (NASDAQ:DXCM)

Beck Bode LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,525 shares of the medical device company’s stock, valued at approximately $1,571,000.

Other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in DexCom by 359.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,456,834 shares of the medical device company’s stock valued at $817,652,000 after purchasing an additional 4,268,926 shares during the last quarter. Nuveen Asset Management LLC boosted its position in shares of DexCom by 1,781.3% during the second quarter. Nuveen Asset Management LLC now owns 1,107,735 shares of the medical device company’s stock worth $165,983,000 after buying an additional 1,048,855 shares during the period. Jennison Associates LLC grew its holdings in shares of DexCom by 211.2% during the second quarter. Jennison Associates LLC now owns 1,391,980 shares of the medical device company’s stock worth $208,574,000 after buying an additional 944,642 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of DexCom by 358.1% during the third quarter. First Trust Advisors LP now owns 279,121 shares of the medical device company’s stock worth $41,656,000 after buying an additional 218,188 shares in the last quarter. Finally, Great Point Partners LLC acquired a new stake in DexCom in the 3rd quarter valued at approximately $22,575,000. 98.20% of the stock is owned by institutional investors.

Shares of DXCM stock traded up $3.95 on Tuesday, hitting $227.87. The company’s stock had a trading volume of 185,115 shares, compared to its average volume of 1,413,019. The company has a debt-to-equity ratio of 1.41, a quick ratio of 5.26 and a current ratio of 5.63. The stock’s 50 day moving average is $184.38 and its 200-day moving average is $157.40. DexCom, Inc. has a fifty-two week low of $105.05 and a fifty-two week high of $229.69. The company has a market capitalization of $20.62 billion, a PE ratio of 759.57 and a beta of 0.76.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.45. The business had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. DexCom’s revenue for the quarter was up 48.6% compared to the same quarter last year. During the same period last year, the firm earned $0.17 earnings per share. On average, research analysts forecast that DexCom, Inc. will post 1.41 earnings per share for the current year.

In other news, EVP Steven Robert Pacelli sold 1,532 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $155.47, for a total transaction of $238,180.04. Following the sale, the executive vice president now directly owns 66,821 shares of the company’s stock, valued at approximately $10,388,660.87. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Nicholas Augustinos sold 1,208 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $145.49, for a total value of $175,751.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 77,459 shares of company stock worth $11,852,977. Company insiders own 0.88% of the company’s stock.

Several analysts have issued reports on DXCM shares. Oppenheimer upped their price target on shares of DexCom from $180.00 to $205.00 in a research report on Thursday, November 7th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $215.00 price objective (up from $190.00) on shares of DexCom in a research report on Thursday, November 7th. BMO Capital Markets upped their price objective on shares of DexCom from $180.00 to $190.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Zacks Investment Research raised shares of DexCom from a “hold” rating to a “buy” rating and set a $154.00 price objective on the stock in a research report on Friday, October 25th. Finally, Robert W. Baird raised their target price on shares of DexCom from $195.00 to $240.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $184.33.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What is the Hang Seng index?  

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.